Latest news

Novo Nordisk bets $550M on RNA tech to revive obesity, diabetes drug pipeline

Novo Nordisk bets $550M on RNA tech to revive obesity, diabetes drug pipeline

Eduardo Longoria
FDA considers noninvasive liver biomarker to accelerate MASH drug trials

FDA considers noninvasive liver biomarker to accelerate MASH drug trials

Eduardo Longoria
Daily Snap - 29. August 2025

Daily Snap - 29. August 2025

Joachim Eeckhout
Daily Snap - 28. August 2025

Daily Snap - 28. August 2025

Joachim Eeckhout
Wugen secures $115M to fast-track first off-the-shelf CAR-T therapy for T-cell cancers

Wugen secures $115M to fast-track first off-the-shelf CAR-T therapy for T-cell cancers

Eduardo Longoria
Biopharma 2024 slowdown threatens Massachusetts’ leadership role

Biopharma 2024 slowdown threatens Massachusetts’ leadership role

Eduardo Longoria
Daily Snap - 27. August 2025

Daily Snap - 27. August 2025

Joachim Eeckhout
Regeneron's cemdisiran achieves Phase 3 win, confirming siRNA’s potential in treating myasthenia gravis

Regeneron's cemdisiran achieves Phase 3 win, confirming siRNA’s potential in treating myasthenia gravis

Eduardo Longoria
Fosun’s $670 million deal with Sitala keeps pointing towards West’s appetite for Chinese innovation

Fosun’s $670 million deal with Sitala keeps pointing towards West’s appetite for Chinese innovation

Eduardo Longoria
Daily Snap - 25. August 2025

Daily Snap - 25. August 2025

Joachim Eeckhout
AbbVie bets $1.2B on psychedelic breakthrough for depression

AbbVie bets $1.2B on psychedelic breakthrough for depression

Joachim Eeckhout
LB Pharma targets IPO lifeline to fund schizophrenia drug trial

LB Pharma targets IPO lifeline to fund schizophrenia drug trial

Joachim Eeckhout
FirstBack
12345678
Next Last